Ekso Bionics Stock Set to Reverse Split on Tuesday, May 27th (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)’s stock is going to reverse split on the morning of Tuesday, May 27th. The 1-15 reverse split was announced on Monday, May 19th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, May 26th.

Ekso Bionics Price Performance

Shares of EKSO opened at $0.28 on Friday. Ekso Bionics has a fifty-two week low of $0.23 and a fifty-two week high of $1.53. The firm’s 50-day simple moving average is $0.42 and its two-hundred day simple moving average is $0.55. The stock has a market cap of $9.83 million, a PE ratio of -0.43 and a beta of 1.09. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The company had revenue of $3.38 million during the quarter, compared to the consensus estimate of $4.62 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. Analysts anticipate that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on EKSO shares. Lake Street Capital reduced their price target on Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. HC Wainwright cut their price objective on shares of Ekso Bionics from $9.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, May 6th. Finally, Wall Street Zen started coverage on shares of Ekso Bionics in a research note on Thursday. They set a “hold” rating for the company.

Hedge Funds Weigh In On Ekso Bionics

An institutional investor recently raised its position in Ekso Bionics stock. Armistice Capital LLC grew its holdings in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 18.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,042,382 shares of the company’s stock after purchasing an additional 316,733 shares during the period. Armistice Capital LLC owned about 7.03% of Ekso Bionics worth $823,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.